Pancreatic Cancer Action Network – AACR Pathway to Leadership Grants Awarded to Early-Career Investigators The Pancreatic Cancer Action Network and the American Association for Cancer Research (AACR) have awarded Jennifer M. Bailey, Ph.D., and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic Cancer Action Network – AACR Pathway to Leadership Grants. [American Association for Cancer Research Press Release] BioSante Pharmaceuticals to Raise $25.1 Million in Registered Direct Offering BioSante Pharmaceuticals, Inc. announced that it has received commitments from several institutional investors to purchase $25.1 million of securities in a registered direct offering. [BioSante Pharmaceuticals, Inc. Press Release] DURATION-6 Top-Line Study Results Announced Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced top-line results from DURATION-6, a head-to-head study designed to compare weekly BYDUREON™ (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, to daily Victoza® (liraglutide (rDNA origin) injection). [Amylin Pharmaceuticals, Inc. Press Release] Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders Omeros Corporation announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors (GPCRs) linked to pancreatic cancer (GPR182) and cognitive disorders (GPR12). [Omeros Corporation Press Release] FDA Accepts New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes AstraZeneca and Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus. [AstraZeneca PLC Press Release] Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer Genus Oncology, LLC announced it has received an Orphan Drug Designation from the FDA’s Office of Orphan Products Development for its Mucin 1 targeting peptide, GO-203-2c, for the treatment of pancreatic cancer. [PR Newswire] Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog® Valeritas, Inc. announced that the U.S. Food and Drug Administration has cleared the company’s V-Go Disposable Insulin Delivery Device for use with Novo Nordisk’s NovoLog® for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin. [Valeritas, Inc. Press Release] Onglyza Becomes the First DPP4 Inhibitor Available for Use in Europe in Type 2 Diabetes Patients with Moderate or Severe Renal Impairment AstraZeneca and Bristol-Myers Squibb Company announced that the European Commission has approved a label update for ONGLYZA® (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. [AstraZeneca PLC Press Release] Omni Bio Pharmaceutical Intends to Expand Type 1 Diabetes Trial to 50 Patients Omni Bio Pharmaceutical, Inc. has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50. [Omni Bio Pharmaceutical, Inc. Press Release] |